New Drug Application (Mirikizumab) Doubles Rates of Remission in Patients with Ulcerative Colitis

A new drug (mirikizumab), investigated by Amsterdam Univerisity Medical Centers together with colleagues around the world, is effective as a treatment against ulcerative colitis, with the clinical trial demonstrating a doubling in the rates of remission, to up to 50%, in certain groups. The results of this clinical trial were published June 29, 2023, in the New England Journal of Medicine.  

Login Or Register To Read Full Story